QTP XR50 mg

Established / FDA-Approved Uses

• Schizophrenia — treatment of schizophrenia in adults and adolescents (13–17 years).
• Bipolar I Disorder, Manic Episodes — acute treatment of manic episodes associated with Bipolar I Disorder, as monotherapy or as an adjunct to lithium or divalproex, in adults and in children/adolescents (10–17 years).
• Bipolar I Disorder or Bipolar II Disorder, Depressive Episodes — acute treatment of depressive episodes associated with bipolar disorder, as monotherapy, in adults.
• Bipolar I Disorder, Maintenance Treatment — as an adjunct to lithium or divalproex, in adults.

Guideline-Supported / Adjunct Use (Extended-Release Formulation)

• Major Depressive Disorder (MDD) — as adjunctive therapy to antidepressants in adults with an inadequate response to antidepressant treatment alone (extended-release formulation only).

QTP XR is not approved for the treatment of dementia-related psychosis in elderly patients (see Boxed Warning under Precautions and Warnings).

Off-Label Use

Low-dose QTP XR is sometimes used off-label (by physician judgment) for insomnia, generalized anxiety disorder, or agitation in certain settings; such use is not FDA-approved and should only be undertaken under close medical supervision.

Each tablet contains Quetiapine Fumarate equivalent to a stated quantity of quetiapine base (commonly available as immediate-release tablets of 25 mg, 100 mg, 200 mg, 300 mg and extended-release tablets of 50 mg, 150 mg, 200 mg, 300 mg, 400 mg). Quetiapine Fumarate is the fumarate salt of quetiapine, a dibenzothiazepine-derivative atypical (second-generation) antipsychotic. Excipients vary by manufacturer and formulation (immediate-release vs. extended-release).

QTP XR is an atypical (second-generation) antipsychotic medicine belonging to the dibenzothiazepineclass. It is used to treat certain serious mental health conditions, including schizophrenia and the manic anddepressive episodes of bipolar disorder, and, in its extended-release form, as an add-on treatment for majordepressive disorder that has not responded adequately to an antidepressant alone.

QTP XR is available as immediate-release tablets (usually taken twice daily) and extended-release tablets(usually taken once daily, typically in the evening). It works by modulating several brain neurotransmitterreceptors rather than a single pathway, which helps reduce symptoms such as hallucinations, delusions, disorganizedthinking, mood instability, mania, and depression associated with these conditions.

Atypical (second-generation/novel) Antipsychotic Agent — Dibenzothiazepine derivative.

Quetiapine Fumarate is metabolized to an active metabolite, norquetiapine, and both compounds are believed tocontribute to its therapeutic effect. Its precise mechanism of action in schizophrenia and bipolar disorder is notfully understood, but is thought to be mediated through a combination of central dopamine type 2 (D2) andserotonin type 2 (5-HT2A) receptor antagonism.

Quetiapine Fumarate and norquetiapine also have affinity for histamine H1 receptors (contributing to sedation), alpha-1 andalpha-2 adrenergic receptors (contributing to orthostatic hypotension), and, to a lesser extent, additionalserotonergic (5-HT1A) and dopaminergic (D1) receptors. It has minimal affinity for muscarinic cholinergic orbenzodiazepine receptors.

Pharmacokinetics

• Absorption: Well absorbed orally; food has minimal effect on immediate-release absorption but increases extended-release peak concentration.
• Metabolism: Extensively hepatic, primarily via cytochrome P450 3A4 (CYP3A4), to the active metabolite norquetiapine and other inactive metabolites.
• Half-life: Approximately 6–7 hours for quetiapine (immediate-release); norquetiapine has a longer half-life (~9–12 hours).
• Excretion: Primarily renal and fecal as metabolites; less than 1% excreted unchanged.

Immediate-release tablets: with or without food, in divided doses. Extended-release tablets: once daily in the evening, on an empty stomach or with a light meal, swallowed whole without crushing, splitting, or chewing.

Clinically Significant Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir and other protease inhibitors): significantly reduce clearance of QTP XR, raising plasma levels and risk of adverse effects; dose reduction of QTP XR is generally required, or the combination should be avoided.
• Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, St. John's Wort): significantly increase clearance of QTP XR, reducing efficacy; higher doses of QTP XR may be needed, guided by clinical response.
• CNS depressants (alcohol, benzodiazepines, opioids, sedative-hypnotics): additive sedation and CNS depression; use with caution.
• Antihypertensive agents: additive blood-pressure–lowering and orthostatic hypotensive effects.
• Levodopa and dopamine agonists: QTP XR may antagonize their effects due to dopamine-receptor blockade.
• Other drugs that prolong the QT interval (certain antiarrhythmics, antibiotics, other antipsychotics): additive risk of QT prolongation; combination requires caution and, where possible, avoidance.

Very Common / Common

• Somnolence and sedation (especially at initiation)
• Dizziness and orthostatic hypotension
• Dry mouth
• Constipation
• Weight gain and increased appetite
• Fatigue
• Elevated blood glucose, lipids (dyslipidemia)
• Tachycardia
• Headache

Less Common but Clinically Important

• Extrapyramidal symptoms (tremor, rigidity, akathisia)
• Elevated prolactin levels
• Hypothyroidism (decreased free T4)
• Leukopenia, neutropenia (rarely agranulocytosis)
• Cataracts (lens changes) with long-term use

Serious / Rare (Seek Immediate Medical Attention)

• Neuroleptic malignant syndrome (fever, muscle rigidity, altered mental status, autonomic instability)
• QT-interval prolongation and abnormal heart rhythm
• Seizures
• Severe allergic reaction (rash, swelling, difficulty breathing)
• Suicidal thoughts or behavior, especially in young people (see Precautions and Warnings)
• Priapism (rare)

See Precautions and Warnings for full detail on the boxed warnings and major risks associated with QTP XR.

Pregnancy: QTP XR should be used during pregnancy only if the potential benefit to the motherclearly justifies the potential risk to the fetus. Neonates exposed to antipsychotic drugs, including QTP XR, duringthe third trimester are at risk of extrapyramidal and/or withdrawal symptoms after delivery (agitation, abnormalmuscle tone, tremor, somnolence, respiratory distress, feeding difficulty); monitor newborns accordingly. Anydecision to use QTP XR in pregnancy should be made in consultation with a physician, weighing the risks of untreatedpsychiatric illness against potential fetal risk.

Lactation: QTP XR and its metabolites are excreted into human breast milk. Because of thepotential for serious adverse reactions in a nursing infant, a decision should be made whether to discontinuenursing or discontinue QTP XR, taking into account the importance of the drug to the mother; this should be decidedin consultation with a physician.

Boxed Warnings

• Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including QTP XR, are at an increased risk of death compared with placebo. QTP XR is not approved for the treatment of dementia-related psychosis.
• Suicidal Thoughts and Behaviors: QTP XR can increase the risk of suicidal thinking and behavior in children, adolescents, and young adults, particularly during the early months of treatment or after dose changes. Close monitoring for clinical worsening and emergence of suicidal thoughts is required, especially at treatment initiation.

Other Important Warnings

• Metabolic changes: Hyperglycemia, new-onset diabetes mellitus, dyslipidemia, and weight gain have been reported; monitor fasting glucose, lipid profile, and weight periodically.
• QT prolongation: Use caution in patients with cardiovascular disease, a history of QT prolongation, electrolyte disturbances (hypokalemia, hypomagnesemia), or when co-administered with other QT-prolonging drugs.
• Orthostatic hypotension and syncope: Most common during initial dose titration and re-titration after interruption of therapy; use with caution in patients at risk of dehydration, cardiovascular or cerebrovascular disease.
• Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal reaction; discontinue immediately if suspected and provide intensive symptomatic treatment.
• Leukopenia, neutropenia, and agranulocytosis: Monitor complete blood counts in patients with pre-existing low white cell counts or a history of drug-induced leukopenia/neutropenia.
• Cataracts: Lens examination is recommended at treatment initiation and periodically during long-term therapy.
• Seizures: Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.
• Hypothyroidism: Thyroid function may be affected; monitor as clinically indicated.
• Sedation and cognitive/motor impairment: May impair judgment, thinking, or motor skills; caution when driving or operating machinery until effects are known.
• Do not stop abruptly: Discontinuation should be gradual and supervised by a physician, as abrupt cessation may cause withdrawal-type symptoms (nausea, vomiting, insomnia) or relapse of the underlying illness.

Overdose of QTP XR may cause exaggeration of its known pharmacological effects, including drowsiness, sedation, tachycardia, hypotension, and impaired airway/consciousness (in severe cases). Overdose is a medical emergency: seek immediate medical attention or contact emergency services/a poison control center. Treatment is supportive — establishing and maintaining a clear airway, ensuring adequate oxygenation and ventilation, and cardiovascular monitoring; there is no specific antidote. Do not attempt to manage a suspected QTP XR overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

QTP XR is approved for schizophrenia in adolescents (13–17 years) and for bipolar mania in children andadolescents (10–17 years). Safety and efficacy have not been established below these age ranges or for otherindications in pediatric patients. Pediatric patients may be more susceptible to somnolence, extrapyramidalsymptoms, elevated prolactin, and weight/metabolic changes; monitor growth, weight, and metabolic parametersclosely.

Geriatric Use

Elderly patients, particularly those with dementia-related psychosis, are at increased risk of death withantipsychotic use (see Boxed Warning); QTP XR is not approved for this population/indication. Elderly patients alsohave increased susceptibility to orthostatic hypotension and sedation; use a lower starting dose and slowertitration.

Hepatic Impairment

Clearance of QTP XR is reduced in hepatic impairment; use a lower starting dose and slower titration, with closeclinical monitoring.

Renal Impairment

No specific dose adjustment is generally required, but caution is advised as clinical experience is limited.

Duration of treatment with QTP XR is individualized based on the indication, clinical response, and physician judgment. Acute episodes (mania, depression, psychotic exacerbation) are typically treated for several weeks to assess response, while maintenance treatment for schizophrenia or bipolar disorder may continue for months to years. QTP XR should not be stopped abruptly; any change in duration or discontinuation should be directed by the prescribing physician.

Atypical (Second-Generation) Antipsychotics; Dibenzothiazepine Derivatives.

Quetiapine Fumarate and its active metabolite norquetiapine act primarily as antagonists at central dopamine D2 and serotonin 5-HT2A receptors, with additional activity at histamine H1, adrenergic alpha-1/alpha-2, and serotonin 5-HT1A receptors, and minimal affinity for muscarinic or benzodiazepine receptors. This multi-receptor antagonism is believed to underlie its antipsychotic, mood-stabilizing, and antidepressant adjunctive effects, though the precise mechanism in humans is not fully established.

C

QTP XR is approved for schizophrenia in adolescents 13–17 years and for acute treatment of bipolar I manic episodes in children and adolescents 10–17 years, using weight/response-guided titration as described in Dosage and Administration. Safety and efficacy have not been established for children below 10 years of age, or for any indication other than these two in patients under 18. Close monitoring for suicidal thoughts/behavior, sedation, weight gain, metabolic changes, and extrapyramidal symptoms is required in pediatric patients.